SAN ANTONIO, Texas — Powerhouse Therapeutics Inc today announced that Chief Executive Officer Vincent Pham will present new preclinical results for the company’s lead candidate, PH102, at the American Association for Cancer Research (AACR) Annual Meeting 2025 in Chicago, IL (April 25-30).
Vincent’s poster, “Supercharging anti-tumor immunity in hepatocellular carcinoma with PH102: A CAR T-cell-based platform,” will be featured in the session “CAR Therapies: Emerging Approaches and Combinations” on Tuesday, April 29, 2025, from 2:00 p.m. to 5:00 p.m. The poster will be displayed in Poster Section 38, Board 20 (Poster #6112). Attendees can locate the exact position using the Poster Hall Map.
PH102 is an autologous CAR T-cell therapy that combines direct tumor lysis with immune activation and micro-environment modulation. In vivo models have demonstrated complete, durable tumor regression without dose-limiting toxicity. “These data strengthen our belief that PH102 can reset the liver tumor immune landscape and deliver meaningful clinical benefit,” said Mr. Pham. “AACR provides an ideal forum to engage collaborators and investors as we prepare for IND submission.”
